Clinical Trial: A Phase IIa Study to Evaluate the Efficacy and Safety of NBQ72S

U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06810804) titled 'A Phase IIa Study to Evaluate the Efficacy and Safety of NBQ72S' on Jan. 22.

Brief Summary: A phase IIa, single-arm, open-label study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer. All patients will receive the study drug every 28 days until withdrawal from treatment.

Study Start Date: Feb. 28

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: NBQ72S

Patients will receive the study drug every 28 days

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Nantong Bencao Quadriga Medical Technology Co. Ltd.

Disclaimer: Curated by HT Syn...